Mersana Therapeutics Inc (MRSN) Receives $14.00 Consensus Target Price from Analysts
Shares of Mersana Therapeutics Inc (NASDAQ:MRSN) have been assigned a consensus recommendation of “Hold” from the seven ratings firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $14.00.
Several research firms recently issued reports on MRSN. Zacks Investment Research downgraded Mersana Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, March 14th. JPMorgan Chase & Co. downgraded Mersana Therapeutics from a “neutral” rating to an “underweight” rating in a report on Monday, March 11th. Finally, Robert W. Baird set a $12.00 price objective on Mersana Therapeutics and gave the company a “buy” rating in a report on Friday, March 8th.
In related news, major shareholder Enterprise Associates 14 New purchased 3,750,000 shares of the business’s stock in a transaction on Tuesday, March 5th. The shares were bought at an average price of $4.00 per share, for a total transaction of $15,000,000.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 39.70% of the stock is currently owned by insiders.
NASDAQ:MRSN opened at $4.95 on Thursday. Mersana Therapeutics has a 52 week low of $2.85 and a 52 week high of $23.96. The company has a current ratio of 6.24, a quick ratio of 6.24 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $236.20 million, a price-to-earnings ratio of -1.77 and a beta of 1.64.
Mersana Therapeutics (NASDAQ:MRSN) last posted its quarterly earnings data on Thursday, May 9th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.03) by $0.73. The firm had revenue of $41.04 million for the quarter, compared to the consensus estimate of $30.11 million. Mersana Therapeutics had a negative return on equity of 57.49% and a negative net margin of 61.68%. On average, research analysts predict that Mersana Therapeutics will post -0.71 EPS for the current fiscal year.
About Mersana Therapeutics
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies.
Recommended Story: Why are gap-down stocks important?
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.